GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gamida Cell Ltd (OTCPK:GMDAQ) » Definitions » PS Ratio

Gamida Cell (Gamida Cell) PS Ratio : 1.42 (As of Apr. 29, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Gamida Cell PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Gamida Cell's share price is $0.0184. Gamida Cell's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01. Hence, Gamida Cell's PS Ratio for today is 1.42.

The historical rank and industry rank for Gamida Cell's PS Ratio or its related term are showing as below:

GMDAQ' s PS Ratio Range Over the Past 10 Years
Min: 0.7   Med: 29.61   Max: 202
Current: 1.42

During the past 8 years, Gamida Cell's highest PS Ratio was 202.00. The lowest was 0.70. And the median was 29.61.

GMDAQ's PS Ratio is ranked better than
89.01% of 992 companies
in the Biotechnology industry
Industry Median: 8.85 vs GMDAQ: 1.42

Gamida Cell's Revenue per Sharefor the three months ended in Dec. 2023 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.01.

Back to Basics: PS Ratio


Gamida Cell PS Ratio Historical Data

The historical data trend for Gamida Cell's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gamida Cell PS Ratio Chart

Gamida Cell Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial - - - - 25.79

Gamida Cell Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 206.00 25.79

Competitive Comparison of Gamida Cell's PS Ratio

For the Biotechnology subindustry, Gamida Cell's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gamida Cell's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gamida Cell's PS Ratio distribution charts can be found below:

* The bar in red indicates where Gamida Cell's PS Ratio falls into.



Gamida Cell PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Gamida Cell's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0184/0.013
=1.42

Gamida Cell's Share Price of today is $0.0184.
Gamida Cell's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Gamida Cell  (OTCPK:GMDAQ) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Gamida Cell PS Ratio Related Terms

Thank you for viewing the detailed overview of Gamida Cell's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Gamida Cell (Gamida Cell) Business Description

Traded in Other Exchanges
N/A
Address
116 Huntington Avenue, 7th Floor, Boston, MA, USA, 02116
Gamida Cell Ltd is a clinical-stage biopharmaceutical company that is pioneering a diverse immunotherapy pipeline of potentially curative cell therapy candidates for patients with solid tumors and blood cancers and other serious blood diseases. The company applies a proprietary expansion platform leveraging the properties of nicotinamide, or NAM, to allogeneic cell sources including umbilical cord blood-derived cells and natural killer, or NK, cells to create cell therapy candidates with the potential to redefine standards of care. Its primary product candidate is Omidubicel, an advanced cell therapy candidate for allogeneic hematopoietic stem cell transplant and GDA-201 is the company's lead investigational NK cell-based cancer immunotherapy product candidate.
Executives
Jeremy Blank director 6446 DREXEL AVENUE, LOS ANGELES CA 90048
Mary Theresa Coelho officer: Chief Financial Officer 52 SUNRISE PARK ROAD, NEW HAMPTON NY 43017
Ronit Simantov officer: CMO & Chief Scientific Officer 1988 CHAPEL STREET, NEW HAVEN CT 06515
Abigail L. Jenkins director, officer: President and CEO C/O GAMIDA CELL LTD., 116 HUNTINGTON AVENUE, BOSTON MA 02116
Stephen T Wills director PALATIN TECHNOLOGIES, INC., 4B CEDAR BROOK DRIVE, CRANBURY NJ 08512
Ivan M. Borrello director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Anat Cohen-dayag director C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Naama Halevi-davidov director C/O KALTURA, INC., 250 PARK AVENUE SOUTH, 10TH FLOOR, NEW YORK NY 10003
Joshua F. Patterson officer: General Counsel C/O AKCEA THERAPEUTICS, INC., 22 BOSTON WHARF ROAD, 9TH FLOOR, BOSTON MA 02210
Bio Medical Investment (1997) Ltd. other: Affiliate of 10% Owner 3 AZRIELI CENTER TRIANGLE, TOWER,, 45TH FLOOR, 132 MENACHEM BEGIN ST., TEL AVIV L3 6702301
Shai Lankry officer: Chief Financial Officer C/O GAMIDA CELL LTD., 5 NAHUM HEFTSADIE STREET, GIVAAT SHAUL, JERUSALEM L3 91340
Ai Gamida Holdings Llc other: Affiliate of 10% Owner 40 WEST 57TH STREET, 28TH FLOOR, NEW YORK NY 10019
Ofer Gonen director 1/3 HIGH-TECH VILLAGE, GIVAT RAM, P.O. BOX 39264, JERUSALEM L3 9139102
Clal Biotechnology Industries Ltd. other: Affiliate of 10% Owner 3AZRIELI CENTER TRIANGLE TOWER 45 FLOOR, TEL AVIV L3 67023
Len Blavatnik 10 percent owner C/O ACCESS INDUSTRIES, 730 FIFTH AVENUE, NEW YORK NY 10019

Gamida Cell (Gamida Cell) Headlines

From GuruFocus

Q3 2023 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Gamida Cell BLA Acceptance Call Transcript

By GuruFocus Research 02-07-2024

Q4 2020 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Q4 2021 Gamida Cell Ltd Earnings Call Transcript

By GuruFocus Research 02-07-2024

Gamida Cell Ltd Omisirge Call Transcript

By GuruFocus Research 02-07-2024